Caxton Associates (New York)’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
$483K Sell
1,854
-3,820
-67% -$1.13M 0.02% 338
2024
Q3
$1.83M Buy
5,674
+3,310
+140% +$1.08M 0.07% 144
2024
Q2
$739K Sell
2,364
-10,822
-82% -$3.18M 0.03% 280
2024
Q1
$3.75M Sell
13,186
-93
-0.7% -$27.2K 0.21% 56
2023
Q4
$3.82M Buy
13,279
+9,804
+282% +$2.67M 0.2% 69
2023
Q3
$934K Sell
3,475
-4,770
-58% -$1.19M 0.13% 164
2023
Q2
$1.83M Buy
+8,245
New +$1.91M 0.27% 76
2023
Q1
Sell
-1,373
Closed -$361K 489
2022
Q4
$361K Buy
+1,373
New +$368K 0.02% 298
2022
Q3
Sell
-3,296
Closed -$802K 474
2022
Q2
$802K Buy
+3,296
New +$808K 0.08% 171
2020
Q3
Sell
-1,929
Closed -$455K 309
2020
Q2
$455K Buy
+1,929
New +$440K 0.04% 157
2018
Q2
Sell
-2,841
Closed -$484K 370
2018
Q1
$484K Sell
2,841
-4,013
-59% -$737K 0.02% 262
2017
Q4
$1.19M Buy
+6,854
New +$1.21M 0.06% 183
2017
Q3
Sell
-2,800
Closed -$482K 483
2017
Q2
$482K Buy
2,800
+300
+12% +$48.8K 0.02% 351
2017
Q1
$410K Buy
+2,500
New +$415K ﹤0.01% 300

Other funds holding AMGN

Caxton Associates (New York)'s AMGN Position: Q4 2024 in Review

Caxton Associates (New York) reduced its Amgen (AMGN) stake by 67% in Q4 2024, selling an estimated $1.13M and leaving 1,854 shares worth $483K. The position accounts for 0.02% of the portfolio, ranked #338.

Caxton Associates (New York) first reported a position in AMGN in Q1 2017 and has held it in 14 quarters since. The position peaked at $3.82M in Q4 2023. 2,855 funds tracked by Wall St. Rank hold AMGN as of Q4 2024.

  • Caxton Associates (New York) held 1,854 shares of Amgen worth $483K as of Q4 2024.
  • Caxton Associates (New York) sold 3,820 Amgen shares in Q4 2024, an estimated $1.13M.
  • Amgen made up 0.02% of Caxton Associates (New York)'s portfolio in Q4 2024, its #338 holding.
  • Caxton Associates (New York) first reported a position in Amgen in Q1 2017 and has held it in 14 quarters since.
  • Caxton Associates (New York)'s Amgen position peaked at $3.82M in Q4 2023.
  • 2,855 funds tracked by Wall St. Rank held Amgen as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.